Fierce Biotech October 25, 2022
Pacific Biosciences raised the curtain on two DNA sequencers: its first short-read device, designed to offer new competition to the industry giant Illumina, as well as a machine poised to be an upgrade over its current long-read hardware.
The latter, the Revio system, will be capable of parsing long strings of genetic code with the capacity to read more than three human genomes per day on average at a cost of less than $1,000 apiece.
It will be geared toward large-scale studies involving human genetics as well as research into cancer and agricultural genomics, the company said in its announcement, citing a throughput of up to 1,300 whole genomes per year delivered at 30x coverage.
PacBio describes the...
Today's Sponsors
Today's Sponsor